Shares of Optimi Health (OPTH) slid 11.4% to $4.45 on June 22, dragging the stock further below its US$6.25 offering price set barely a month ago. The Vancouver-based manufacturer of pharmaceutical-grade psilocybin and MDMA products completed an oversubscribed Nasdaq debut on May 20, but investors who bought in at the IPO are now staring at a roughly 29% loss — and the sell-off appears stock-specific, not market-driven.
• The IPO Never Actually Traded Above Its Own Price. Optimi began trading on Nasdaq on May 20 at a $6.25 offering price, but the stock's all-time high of $6.12 — recorded two days later — was already below that level, signaling that public-market investors immediately questioned the valuation set by underwriter Joseph Gunnar. Today's price means the company's market capitalization sits around $25 million, based on approximately 5.6 million shares outstanding.
• Quarterly Revenue Is Barely a Rounding Error. Optimi reported fiscal Q2 2026 earnings on June 1, posting a loss per share of ($0.36) — missing estimates — on revenue of just $0.07 million.
Full-year fiscal 2025 revenue was only $426,301. At a price-to-sales ratio near 70x, investors are paying almost entirely for a future that depends on regulatory breakthroughs in psychedelic therapy, not current business performance.
• The Cash Buys Runway, but Dilution Stings. A 1-for-30 reverse share split preceded the offering, leaving roughly 3.2 million shares outstanding before the deal. The 2.4 million new shares expanded the count by about 75% — a level Simply Wall St flagged as substantial shareholder dilution. CEO Dane Stevens called the raise a source of "ample runway to scale over the next few years," with proceeds earmarked for scaling production, U.S. market expansion, and working capital.
• The Regulatory Bet Is Real but Unproven. A U.S. Executive Order in April named ibogaine among psychedelic therapies prioritized for accelerated FDA review.
Australia's updated prescriber framework also broadened therapist eligibility for psilocybin and MDMA. These are genuine catalysts, but Optimi's products reach only a handful of patients through special-access programs — current revenue is under US$1 million — making it a high-conviction bet on a regulatory wave that hasn't arrived yet.
The bottom line: Optimi is a pre-revenue company trading on hope in a speculative sector. The Nasdaq listing widened its investor base, but until sales catch up to the story, every bounce risks another unwind.